Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Lymphoid 1

Conditions

Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

elotuzumab 4Bortezomib 4Lenalidomide 3Dexamethasone 3talquetamab 2selinexor 2pomalidomide 2carfilzomib 2Panobinostat 2venetoclax 1ulocuplumab 1plerixafor 1idecabtagene vicleucel 1fludarabine phosphate 1daratumumab 1ceritinib 1belantamab mafodotin 1Whole-Body Irradiation 1Tacrolimus 1Prednisone 1Mycophenolic Acid 1Melphalan 1Cytarabine 1Crizotinib 1Cord Blood Stem Cell Transplantation 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × ceritinib × Plasma cell × Clear all
NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

Novartis

No longer available
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡